➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Johnson and Johnson
Harvard Business School
Baxter
Express Scripts

Last Updated: August 1, 2021

DrugPatentWatch Database Preview

Details for Patent: 9,126,941


Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,126,941
Title:Treatment of hyperproliferative disorders with diarylhydantoin compounds
Abstract: The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.
Inventor(s): Sawyers; Charles L. (New York, NY), Jung; Michael E. (Los Angeles, CA), Chen; Charlie D. (Los Angeles, CA), Ouk; Samedy (Los Angeles, CA), Tran; Chris (New York, NY), Wongvipat; John (Nanuet, NY)
Assignee: The Regents of the University of California (Oakland, CA)
Application Number:13/448,964
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,126,941
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Dosage form;

Drugs Protected by US Patent 9,126,941

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Astellas XTANDI enzalutamide CAPSULE;ORAL 203415-001 Aug 31, 2012 AB RX Yes Yes ⤷  Try it Free ⤷  Try it Free TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC) ⤷  Try it Free
Astellas XTANDI enzalutamide CAPSULE;ORAL 203415-001 Aug 31, 2012 AB RX Yes Yes ⤷  Try it Free ⤷  Try it Free THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC). ⤷  Try it Free
Astellas XTANDI enzalutamide CAPSULE;ORAL 203415-001 Aug 31, 2012 AB RX Yes Yes ⤷  Try it Free ⤷  Try it Free THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
Express Scripts
Baxter
Colorcon
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.